Cancer Genetics, Inc.

Cancer Genetics, Inc. has 1 AI-enabled medical device on the FDA list. The first decision was on March 15, 2018 and the most recent on March 15, 2018 (Tissue of Origin Test Kit-FFPE). Its most common review panel is Clinical Toxcicology (1 device).